Use of the complex between prostate specific antigen and α1-protease inhibitor for screening prostate cancer

Journal of Urology

Volumn 164, Issue 6, 2000, Pages 1956-1960

  Finne, Patrik ^a,b   Zhang, Wan Ming ^a,b   Auvinen, Anssi ^a,b,c   Leinonen, Jari ^a,b   Määttänen, Liisa ^a,b   Rannikko, Sakari ^a,b   Tammela, Teuvo L J ^a,b   Stenman, Ulf Håkan ^a,b  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^b TAMPERE UNIVERSITY HOSPITAL   (Finland)

^c Helsinki University Central Hospital ^*

Author keywords

Alpha 1 antitrypsin; Mass screening; Prostate specific antigen; Prostatic neoplasms

Indexed keywords

ALPHA 1 ANTITRYPSIN; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ANTIGEN DETECTION; ARTICLE; CANCER MORTALITY; CANCER SCREENING; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; HUMAN; IMMUNOASSAY; MAJOR CLINICAL STUDY; MALE; MASS SCREENING; PRIORITY JOURNAL; PROSTATE CANCER; RECEIVER OPERATING CHARACTERISTIC; REGRESSION ANALYSIS;

EID: 0033762973     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-5347(05)66927-3     Document Type: Article

References (19)

1. Cancer incidence in five continents
2. Optimized strategy for detection of early stage, curable prostate cancer: Role of prescreening with prostate-specific antigen
3. The European Randomized Study of Screening for Prostate Cancer (ERSPC)
4. Measurement of prostate-specific antigen in serum as a screening test for prostate cancer
5. European randomized study of prostate cancer screening: First-year results of the Finnish trial
6. A complex between prostate-specific antigen and α1-antichymotrypsin is the major form of prostate-specific antigen in serum of patients with prostatic cancer: Assay of the complex improves clinical sensitivity for cancer
7. Prostate-specific antigen in serum occurs predominantly in complex with α1-antichymotrypsin
8. Characterization and immunological determination of the complex between prostate-specific antigen and α2-macroglobulin
9. Measurement of the complex between prostate-specific antigen and α1-protease inhibitor in serum
10. Double-label time-resolved immunofluorometric assay of prostate-specific antigen and of its complex with α1-antichymotrypsin
11. Serum prostate specific antigen complexed to α1-antichymotrypsin as an indicator of prostate cancer
12. Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: A prospective multicenter clinical trial
13. Evaluation of percentage of free serum prostate-specific antigen to improve specificity of prostate cancer screening
14. Usefulness of the ratio free/total prostate-specific antigen in addition to total PSA levels in prostate cancer screening
15. Time-resolved immunofluorometric assays for trypsinogen-1 and 2 in serum reveal preferential elevation of trypsinogen-2 in pancreatitis
16. The meaning and use of the area under a receiver operating characteristic (ROC) curve
17. Estimation of prostate cancer probability by logistic regression: Free and total prostate-specific antigen, digital rectal examination, and heredity are significant variables
18. Predicting the outcome of prostate biopsy in screen-positive men by a multilayer perceptron network